BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1331 related articles for article (PubMed ID: 31102428)

  • 1. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
    Ohue Y; Nishikawa H
    Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumors establish resistance to immunotherapy by regulating T
    Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop.
    Marangoni F; Zhakyp A; Corsini M; Geels SN; Carrizosa E; Thelen M; Mani V; Prüßmann JN; Warner RD; Ozga AJ; Di Pilato M; Othy S; Mempel TR
    Cell; 2021 Jul; 184(15):3998-4015.e19. PubMed ID: 34157302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory T cells: a potential target in cancer immunotherapy.
    Shitara K; Nishikawa H
    Ann N Y Acad Sci; 2018 Apr; 1417(1):104-115. PubMed ID: 29566262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
    Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
    Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
    Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
    Wang H; Franco F; Ho PC
    Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
    Kumar P; Bhattacharya P; Prabhakar BS
    J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression.
    Yamaguchi T; Kishi A; Osaki M; Morikawa H; Prieto-Martin P; Wing K; Saito T; Sakaguchi S
    Proc Natl Acad Sci U S A; 2013 Jun; 110(23):E2116-25. PubMed ID: 23690575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cells in cancer immunotherapy.
    Tanaka A; Sakaguchi S
    Cell Res; 2017 Jan; 27(1):109-118. PubMed ID: 27995907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting regulatory T cells in tumors.
    Liu C; Workman CJ; Vignali DA
    FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors.
    Robles O; Jackson JJ; Marshall L; Talay O; Chian D; Cutler G; Diokno R; Hu DX; Jacobson S; Karbarz E; Kassner PD; Ketcham JM; McKinnell J; Meleza C; Reilly MK; Riegler E; Shunatona HP; Wadsworth A; Younai A; Brockstedt DG; Wustrow DJ; Zibinsky M
    J Med Chem; 2020 Aug; 63(15):8584-8607. PubMed ID: 32667798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.
    Togashi Y; Shitara K; Nishikawa H
    Nat Rev Clin Oncol; 2019 Jun; 16(6):356-371. PubMed ID: 30705439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.